-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1919 Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts
Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical Research
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Hassan Kawtharany1*, Muayad Azzam, MD2*, Jamil Nazzal, MD1*, Vishal Kukreti, MD, MSc3, Matthew D. Seftel, MD, FRCP, FRCPC, MPH4, Qais Hamarsha, MD1*, Aseel Alkhader, MD1*, Tala Khraise, MD5*, Mohammad Mahmoud AlMasri, MD6*, Hadi Khaled Abou Zeid, MD7*, Iktimal Alwan, MD8*, Mhd Amin Alzabibi, MD9*, Noor Jaber1*, Laura Darwish10*, Faizi Jamal, MD11*, Noel Dasgupta, MD12*, Nitasha Sarswat, MD13*, Alfredo H. De La Torre, MD14, Maria Adela Aguirre, MD, PhD15*, Deborah Boedicker16*, Naresh Bumma, MD17, Antonia Carroll, MD18*, Raymond Comenzo, MD19, Joselle Cook, MBBS20, Angela Dispenzieri, MD20, Jack Khouri, MD21, Maria M. Picken, MD, PhD22*, Shahzad Raza, MD21, Nelson Leung, MD20, Vaishali Sanchorawala23, Hira Shaikh, MD24, Daulath Singh, MD25* and Reem A Mustafa, MD, PhD, MPH26*

1Evidence-Based Practice and Impact Center, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
2Evidence-Based Practice and Impact Center, Department of Internal Medicine, University of Kansas Medical Center, Overland Park, KS
3Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
4Department of Medicine, University of British Columbia, Vancouver, CAN
5Northwest Health, Porter County, IN
6King Hussein Cancer Center, Amman, Jordan
7University of Balamand, Balamand, Lebanon
8AdventHealth, Tampa
9Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
10Blue Valley Southwest, Kansas city
11Division of Cardiology, Department of Medicine, City of Hope National Medical Center, Duarte, CA
12Indiana University School of Medicine, Indianapolis, IN
13Advanced Heart Failure, Mechanical Circulatory Support and Transplantation, Division of Cardiology, The University of Chicago, Chicago, IL
14QEII Health Sciences Centre, Halifax, NS, CAN
15Internal Medicine Department, Hospital Italiano de Buenos Aires, BUENOS AIRES, AL, ARG
16Mackenzie’s Mission, Great Falls, VA
17The Ohio State University Comprehensive Cancer Center, COLUMBUS, OH
18Department of Neurology and Neurophysiology, St Vincent’s Hospital, Sydney, AUS
19Tufts Medical Center, Boston, MA
20Division of Hematology, Mayo Clinic, Rochester, MN
21Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
22Loyola University Medical Center, Maywood, IL
23Section of Hematology and Medical Oncology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA
24Division of Hematology, Oncology and Bone Marrow Transplantation, University of Iowa, Coralville, IA
25Mission Cancer + Blood, Des Moines, IA
26Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Centre, Kansas City, KS

Introduction: Although endomyocardial biopsy is the gold standard, echocardiography, and Cardiac Magnetic Resonance (CMR) play a pivotal role in the diagnosis of cardiac amyloidosis. In this systematic review, we aim to estimate the diagnostic test accuracy (DTA) of CMR and echocardiography for cardiac amyloidosis.

Methods: As part of the American Society of Hematology guidelines on the diagnosis of Amyloidosis, we searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials from inception till January 2024 for relevant studies. Two reviewers independently performed title and abstract screening and full-text article screening on LASER Al and extracted relevant data using a piloted Excel sheet. We performed statistical pooling using Stata 18.0 software. We evaluated risk of bias using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) and used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess the certainty of the evidence. We report diagnostic test accuracy as sensitivity (95% confidence interval) and specificity (95% confidence interval).

Results: After screening 29,237, we included 9 studies assessing DTA of late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) using an endomyocardial biopsy (EMB) as a reference test in patients with amyloidosis (light chain and ATTR). The majority of studies didn’t report on the type of amyloidosis where only 2 out of 9 were in patients with light chain amyloidosis. The pooled estimates for sensitivity and specificity of LGE are 0.95 (0.88. 0.98), and 0.81 (0.60, 0.92), respectively. We did a sensitivity analysis and included only LGE suggestive for amyloidosis which didn’t change sensitivity but led to an increase in specificity for amyloidosis to 0.87 (0.76, 0.94), respectively. The pooled estimates were based on moderate certainty in the evidence.

For 2-dimensional echocardiography, we addressed DTA for different echocardiographic findings and we did not limit the reference to EMB. A panel of experts judged whether the reference was acceptable or not. Acceptable reference was EMB alone or a combination of extracardiac biopsy plus cardiac imaging (CMR or echocardiography) with or without positive cardiac biomarkers (troponin or BNP or NT-proBNP).

Six studies (n=2063) addressed interventricular septum thickness (IVS), sensitivity was 0.77 (0.69, 0.84) and specificity was 0.71 (0.60, 0.81). 4 out of 6 studies used 12 mm as a cutoff while the other 2 studies used 13 mm as a cutoff. Only 2 studies (n=1667) assessed the DTA of posterior wall thickness (PWT), with sensitivity ranging from 0.76 to 1.00, and specificity ranging from 0.84 to 0.89.

Six studies (n=438) addressed diastolic dysfunction (grade 2,3), with a sensitivity of 0.71 (0.40, 0.90), and specificity of 0.75 (0.64, 0.84). 7 studies (n=472) reported DTA of only diastolic dysfunction grade 3. When compared to diastolic dysfunction (grade 2,3, sensitivity decreases to 0.42 (0 28. 0.58) and specificity increases to 0.89 (0.83. 0.94). For E/A ratio, only 2 studies (n=127) were included. Sensitivity ranged from 0.45 to 0.65, and specificity ranged from 0.85 to 0.98.

Four studies (n=1596) yielded a sensitivity of 0.86 (0.65, 0.95) and specificity of 0.76 (0.55, 0.89) of left ventricular global longitudinal strain (GLS). All except one used -17% as a cutoff for GLS.

For apical sparing on GLS, pooled estimates from 8 studies (n=2253) led to a sensitivity of 0.72 (0.64, 0.78) and specificity of 0.78 (0.64, 0.88). There was a variation of cutoff across studies. The certainty of evidence for echocardiographic findings was low to moderate.

Conclusion: CMR is a more accurate test with better performance compared to echocardiography.

Disclosures: Seftel: Novartis: Other: Meal at CME event; Astrazeneca: Other: Meal at CME event. Jamal: Janssen: Consultancy. Dasgupta: Intellia: Other: Advisory Board; Siemens: Other: Adjudicator; Astra Zeneca: Other: Advisory Board; NovoNordisk: Other: Advisory Board; Eidos: Other: Advisory Board; Alnylam: Other: Advisory Board. Sarswat: Eidos: Consultancy, Membership on an entity's Board of Directors or advisory committees; Alnylam: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novo Nordisk: Consultancy, Membership on an entity's Board of Directors or advisory committees. Aguirre: Pfizer: Honoraria; PTC Bio: Honoraria. Bumma: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Carroll: Janssen: Other: Travel Support; CSL Behring: Honoraria; Alnylam: Other: Advisory Committee. Cook: Geron Corp: Other: Held $600 Geron Stock for one week and sold without profit . Dispenzieri: Janssen: Research Funding; Takeda: Consultancy, Research Funding; Alnylam: Research Funding; Alexion: Consultancy, Research Funding; HaemaloiX: Research Funding; BMS: Consultancy, Research Funding; Pfizer: Research Funding. Khouri: GPCR Therapeutics, Inc.: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Consultant; Prothena: Honoraria; Legend: Membership on an entity's Board of Directors or advisory committees. Raza: Pfizer: Consultancy, Honoraria; Prothena Biosciences: Consultancy; Kite Pharma: Consultancy. Leung: Checkpoint Therapeutics: Current holder of stock options in a privately-held company; AbbVie: Current holder of stock options in a privately-held company. Sanchorawala: Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena, AstraZeneca, Nexcella: Membership on an entity's Board of Directors or advisory committees; Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, Alexion: Research Funding; Pfizer, Janssen, Attralus, GateBio, Abbvie, BridgeBio: Consultancy.

*signifies non-member of ASH